Spotlight: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia (Aggarwal, et al, 2025)
"The study demonstrated improvements in subjective sleep quality and other captured PROMs in insomnia patients treated with cannabis-based medicinal products."
Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)
"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)
"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."
Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)
"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "
Spotlight: Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics? (Garcia-Romeu, 2025)
The relative contribution of drug vs. psychological support remains to be determined, though preliminary data indicate the therapeutic relationship can impact treatment outcomes [12], and factors such as environment, personality, and mindset can influence subjective drug effects.
